Prothena | PRTA - Equity Capital And Reserves


Prothena reported $312.62M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Exelixis USD 1.94B 225.57M Mar/2026
Immunic USD 151.23M 157.91M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Prothena USD 312.62M 32.14M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026